Saccharomyces boulardii decreases inflammation and intestinal colonization by Candida albicans in a mouse model of chemically-induced colitis

References

• Bodey GP. Candidiasis in cancer patients. Am J Med 1984; 77: 13–19
   PubMed Web of Science ®Google Scholar
• Davies AN, Brailsford SR, Beighton D. Oral candidosis in patients with advanced cancer. Oral Oncol 2006; 42: 698–702
   PubMed Web of Science ®Google Scholar
• Myerowitz RL, Pazin GJ, Allen CM. Disseminated candidiasis. Changes in incidence, underlying diseases, and pathology. Am J Clin Pathol 1977; 68: 29–38
   PubMed Web of Science ®Google Scholar
• Verghese A, Prabhu K, Diamond RD, Sugar A. Synchronous bacterial and fungal septicemia. A marker for the critically ill surgical patient. Am Surg 1988; 54: 276–283
   Google Scholar
• de Repentigny L, Phaneuf M, Mathieu LG. Gastrointestinal colonization and systemic dissemination by Candida albicans and Candida tropicalis in intact and immunocompromised mice. Infect Immun 1992; 60: 4907–4914
   Google Scholar
• Calderone R. Candida and Candidiasis. Washington, DC 2002.
   Google Scholar
• Cole GT, Halawa AA, Anaissie EJ. The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside. Clin Infect Dis 1996; 22: S73–88
   PubMed Web of Science ®Google Scholar
• Stone HH, Geheber CE, Kolb LD, Kitchens WR. Alimentary tract colonization by Candida albicans. J Surg Res 1973; 14: 273–276
   PubMed Web of Science ®Google Scholar
• Czerucka D, Rampal P. Experimental effects of Saccharomyces boulardii on diarrheal pathogens. Microbes Infect 2002; 4: 733–739
   PubMed Web of Science ®Google Scholar
• Buts JP, De Keyser N. Effects of Saccharomyces boulardii on intestinal mucosa. Dig Dis Sci 2006; 51: 1485–1492
   PubMed Web of Science ®Google Scholar
• Vidon N, Huchet B, Rambaud JC. [Influence of Saccharomyces boulardii on jejunal secretion in rats induced by cholera toxin]. Gastroenterol Clin Biol 1986; 10: 13–16
   PubMedGoogle Scholar
• Massot J, Desconclois M, Astoin J. [Protection by Saccharomyces boulardii against Escherichia coli diarrhea in newborn mice]. Ann Pharm Fr 1983; 40: 445–449
   Google Scholar
• Elmer GW, Corthier G. Modulation of Clostridium difficile induced mortality as a function of the dose and the viability of the Saccharomyces boulardii used as a preventative agent in gnotobiotic mice. Can J Microbiol 1991; 37: 315–317
   PubMed Web of Science ®Google Scholar
• Algin C, Sahin A, Kiraz N, Sahinturk V, Ihtiyar E. Effectiveness of bombesin and Saccharomyces boulardii against the translocation of Candida albicans in the digestive tract in immunosuppressed rats. Surg Today 2005; 35: 869–873
   Google Scholar
• Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000; 45: 1462–1464
   PubMed Web of Science ®Google Scholar
• Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003; 15: 697–698
   PubMed Web of Science ®Google Scholar
• Standaert-Vitse A, Jouault T, Vandewalle P, et al. Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn's disease. Gastroenterology 2006; 130: 1764–1775
   PubMed Web of Science ®Google Scholar
• Gillum AM, Tsay EY, Kirsch DR. Isolation of the Candida albicans gene for orotidine-5′-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet 1984; 198: 179–182
   PubMedGoogle Scholar
• Sendid B, Francois N, Standaert A, et al. Prospective evaluation of the new chromogenic medium CandiSelect 4 for differentiation and presumptive identification of the major pathogenic Candida species. J Med Microbiol 2007; 56: 495–499
   PubMed Web of Science ®Google Scholar
• Nishiyama Y, Aoki Y, Yamaguchi H. Morphological aspects of cell wall formation during protoplast regeneration in Candida albicans. J Electron Microsc (Tokyo) 1995; 44: 72–78
   PubMedGoogle Scholar
• Hartmann G, Bidlingmaier C, Siegmund B, et al. Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. J Pharmacol Exp Ther 2000; 292: 22–30
   PubMed Web of Science ®Google Scholar
• Odds FC. Candida and Candidosis2nd ed. Bailliere Tindall, Philadelphia 1988
   Google Scholar
• Voss A, Hollis RJ, Pfaller MA, Wenzel RP, Doebbeling BN. Investigation of the sequence of colonization and candidemia in nonneutropenic patients. J Clin Microbiol 1994; 32: 975–980
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut?. Clin Infect Dis 2001; 33: 1959–1967
   PubMed Web of Science ®Google Scholar
• Bille J. [Systemic mycotic infections: epidemiology and diagnostic criteria]. Schweiz Med Wochenschr 1995; 125: 1123–1129
   Google Scholar
• Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546–1554
   PubMed Web of Science ®Google Scholar
• Olaechea PM, Palomar M, Leon-Gil C, et al. Economic impact of Candida colonization and Candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis 2004; 23: 323–330
   PubMedGoogle Scholar
• Ducluzeau R, Bensaada M. [Comparative effect of a single or continuous administration of “Saccharomyces boulardii” on the establishment of various strains of “candida” in the digestive tract of gnotobiotic mice]. Ann Microbiol (Paris) 1982; 133: 491–501
   PubMedGoogle Scholar
• Brugier S, Patte F. Antagonisme in vitro entre l'Ultra-levure et différents germes bacteriens. Méd Paris 1975; 45: 3–8
   Google Scholar
• Shanahan F. Crohn's disease. Lancet 2002; 359: 62–69
   PubMed Web of Science ®Google Scholar
• Shanahan F. Nutrient tasting and signaling mechanisms in the gut V. Mechanisms of immunologic sensation of intestinal contents. Am J Physiol Gastrointest Liver Physiol 2000; 278: G191–196
   Google Scholar
• Buts JP. Mechanisms of action of biotherapeutic agents. Humana Press, Totowa, NJ 1999
   Google Scholar
• Buts JP, Bernasconi P, Vaerman JP, Dive C. Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci 1990; 35: 251–256
   PubMed Web of Science ®Google Scholar
• Hennequin C, Thierry A, Richard GF, et al. Microsatellite typing as a new tool for identification of Saccharomyces cerevisiae strains. J Clin Microbiol 2001; 39: 551–559
   PubMed Web of Science ®Google Scholar
• M Maillée PVN, Bertout S, Vaillant C, Bastide JM. Genotypic study of Saccharomyces boulardii compared to the Saccharomyces sensu stricto complex species. J Mycol Med 2001; 11: 19–25
   Google Scholar
• Fietto JL, Araujo RS, Valadao FN, et al. Molecular and physiological comparisons between Saccharomyces cerevisiae and Saccharomyces boulardii. Can J Microbiol 2004; 50: 615–621
   PubMed Web of Science ®Google Scholar
• Castagliuolo I, LaMont JT, Nikulasson ST, Pothoulakis C. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun 1996; 64: 5225–5232
   PubMed Web of Science ®Google Scholar
• Zwolinska-Wcislo M, Budak A, Trojanowska D, et al. [The influence of Candida albicans on the course of ulcerative colitis]. Przegl Lek 2006; 63: 533–538
   Google Scholar
• Nagy F, Szenasi Z, Szollosy E, Kiss I, Varro V. Determination and kinetics of antibody response to Candida albicans in ulcerative colitis. Hepatogastroenterology 1989; 36: 182–184
   Google Scholar
• Kalkanci A, Tuncer C, Degertekin B, et al. Detection of Candida albicans by culture, serology and PCR in clinical specimens from patients with ulcerative colitis: re-evaluation of an old hypothesis with a new perspective. Folia Microbiol (Praha) 2005; 50: 263–267
   Google Scholar
• Joossens S, Suenaert P, Noman M, Vermeire S, Rutgeerts P. Saccharomyces boulardii in Crohn's disease: effect on anti-Saccharomyces cerevisiae antibodies and intestinal permeability. Inflamm Bowel Dis 2005; 11: 863–864
   Google Scholar
• Sun FF, Lai PS, Yue G, et al. Pattern of cytokine and adhesion molecule mRNA in hapten-induced relapsing colon inflammation in the rat. Inflammation 2001; 25: 33–45
   PubMedGoogle Scholar
• Murano M, Maemura K, Hirata I, et al. Therapeutic effect of intracolonically administered nuclear factor kappa B (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis. Clin Exp Immunol 2000; 120: 51–58
   PubMed Web of Science ®Google Scholar
• Reed KL, Fruin AB, Gower AC, et al. NF-kappaB activation precedes increases in mRNA encoding neurokinin-1 receptor, proinflammatory cytokines, and adhesion molecules in dextran sulfate sodium-induced colitis in rats. Dig Dis Sci 2005; 50: 2366–2378
   PubMedGoogle Scholar
• Sougioultzis S, Simeonidis S, Bhaskar KR, et al. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. Biochem Biophys Res Commun 2006; 343: 69–76
   PubMed Web of Science ®Google Scholar
• Dahan S, Dalmasso G, Imbert V, et al. Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells. Infect Immun 2003; 71: 766–773
   PubMed Web of Science ®Google Scholar
• Dalmasso G, Cottrez F, Imbert V, et al. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology 2006; 131: 1812–1825
   PubMed Web of Science ®Google Scholar
• Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004; 118: 229–241
   PubMed Web of Science ®Google Scholar
• Netea MG, Van Der Graaf CA, Vonk AG, et al. The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J Infect Dis 2002; 185: 1483–1489
   PubMed Web of Science ®Google Scholar
• Thoma-Uszynski S, Stenger S, Takeuchi O, et al. Induction of direct antimicrobial activity through mammalian toll-like receptors. Science 2001; 291: 1544–1547
   PubMed Web of Science ®Google Scholar
• Netea MG, Sutmuller R, Hermann C, et al. Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. J Immunol 2004; 172: 3712–3718
   PubMed Web of Science ®Google Scholar
• Hoag KA, Street NE, Huffnagle GB, Lipscomb MF. Early cytokine production in pulmonary Cryptococcus neoformans infections distinguishes susceptible and resistant mice. Am J Respir Cell Mol Biol 1995; 13: 487–495
   PubMed Web of Science ®Google Scholar
• Hsieh CS, Macatonia SE, O'Garra A, Murphy KM. T cell genetic background determines default T helper phenotype development in vitro. J Exp Med 1995; 181: 713–721
   PubMed Web of Science ®Google Scholar
• Huffnagle GB, Boyd MB, Street NE, Lipscomb MF. IL-5 is required for eosinophil recruitment, crystal deposition, and mononuclear cell recruitment during a pulmonary Cryptococcus neoformans infection in genetically susceptible mice (C57BL/6). J Immunol 1998; 160: 2393–2400
   PubMed Web of Science ®Google Scholar
• Liu T, Matsuguchi T, Tsuboi N, Yajima T, Yoshikai Y. Differences in expression of toll-like receptors and their reactivities in dendritic cells in BALB/c and C57BL/6 mice. Infect Immun 2002; 70: 6638–6645
   PubMed Web of Science ®Google Scholar
• Berg R, Bernasconi P, Fowler D, Gautreaux M. Inhibition of Candida albicans translocation from the gastrointestinal tract of mice by oral administration of Saccharomyces boulardii. J Infect Dis 1993; 168: 1314–1318
   PubMed Web of Science ®Google Scholar
• Herrero E, de la Torre MA, Valentin E. Comparative genomics of yeast species: new insights into their biology. Int Microbiol 2003; 6: 183–190
   Google Scholar